Antimicrobial Use during the SARS-CoV-2 Pandemic in a Greek Tertiary University Hospital
Dimitrios Biros, Sempastian Filippas-Ntekouan, Diamantina Limperatou, Angelos Liontos, Rafail Matzaras, Konstantina-Helen Tsarapatsani, Nikolaos-Gavriel Kolios, Christiana Pappa, Maria Nasiou, Eleni Pargana, Ilias Tsiakas, Valentini Samanidou, Lazaros Athanasiou, Revekka Konstantopoulou, Haralampos Milionis, Eirini Christaki- Virology
- Microbiology (medical)
- Microbiology
In cases of SARS-CoV-2 hospitalization, despite low bacterial co-infection rates, antimicrobial use may be disproportionately high. Our aim was to quantify such usage in COVID-19 patients and identify factors linked to increased antibiotic use. We retrospectively studied patients with SARS-CoV-2 infection who were hospitalized at our institution during the pandemic. In the initial two waves of the pandemic, antimicrobial use was notably high (89% in the first wave and 92% in the second), but it decreased in subsequent waves. Elevated procalcitonin (>0.5 μg/mL) and C-reactive protein (>100 mg/L) levels were linked to antibiotic usage, while prior vaccination reduced antibiotic incidence. Antimicrobial use decreased in the pandemic, suggesting enhanced comprehension of SARS-CoV-2′s natural course. Additionally, it was correlated with heightened SARS-CoV-2 severity, elevated procalcitonin, and C-reactive protein levels.